During the&nbsp;<a href="https://lymphomahub.com/congresses/ash/ash-2025" rel="noopener noreferrer" target="_blank">67th American Society of Hematology&nbsp;(ASH)&nbsp;Annual Meeting&nbsp;and Exposition</a>,&nbsp;December 6–9, 2025, Orlando, US,&nbsp;the&nbsp;Lymphoma&nbsp;Hub was pleased to speak with&nbsp;<a href="https://lymphomahub.com/contributors/alexey-v-danilov" rel="noopener noreferrer" target="_blank">Alexey Danilov</a>,&nbsp;City of Hope Comprehensive Cancer Center, Duarte, US. We asked,&nbsp;What&nbsp;are the latest updates from the phase I&nbsp;<a href="https://lymphomahub.com/trials/nx-5948-301" rel="noopener noreferrer" target="_blank">NX-5948-301</a>&nbsp;trial of&nbsp;<a href="https://lymphomahub.com/therapeutics/kinase-inhibitors/nx-5948" rel="noopener noreferrer" target="_blank">bexobrutideg</a>&nbsp;in patients with relapsed/refractory&nbsp;(R/R)&nbsp;<a href="https://lymphomahub.com/subtypes/clls/cll" rel="noopener noreferrer" target="_blank">chronic lymphocytic leukemia</a>&nbsp;(CLL)?&nbsp; This educational resource is independently supported by&nbsp;Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were&nbsp;allowed&nbsp;no influence on the content of this resource.<hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

ASH 2025 | Key highlights in lymphoma and CLL

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.